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Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell
lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI).    
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes
between pemetrexed plus cisplatin combination therapy followed by maintenance peme-
trexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary
objective was progression-free survival (PFS), and secondary objectives included overall 
response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety
and toxicity profiles. 
Results
A total of 96 patients were randomized, and 91 patients were treated at 14 centers in Korea.
The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066).
With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4
months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC
and P arms, respectively (p=0.787). Adverse events  grade 3 were reported in 12 patients
(26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time
trends of HRQOL were not significantly different between the two arms.   
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after first-
line EGFR-TKI might not be improved by adding cisplatin.
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Introduction
Somatic mutations in the epidermal growth factor receptor
(EGFR) gene account for about 30%-40% of non-small cell
lung cancers (NSCLCs) in Asian patients and 10%-15% of
NSCLCs in Caucasian patients [1,2]. The introduction of first-
generation EGFR tyrosine kinase inhibitors (TKIs; gefitinib,
erlotinib) and second-generation TKIs (afatinib) for the treat-
ment of NSCLC patients with a sensitizing EGFR mutation
has demonstrated a high response rate and prolonged pro-
gression-free survival (PFS) compared with platinum dou-
blet as first-line therapy [3-5].  
However, almost all patients eventually develop acquired
resistance to EGFR-TKIs, with a median PFS of 9-14 months
[6-8]. A randomized phase III trial comparing pemetrexed/
cisplatin/gefitinib with pemetrexed/cisplatin/placebo did
not show improvement of clinical outcome in patients who
showed disease progression on EGFR-TKI; therefore, plat-
inum doublet chemotherapy is considered the standard
treatment for this patient population [9]. Recently, a third-
generation EGFR-TKI (osimertinib) demonstrated significant
improvement in response rate and PFS compared with plat-
inum doublet chemotherapy in patients harboring the T79-
0M mutation, which is the most common resistance mecha-
nism to first- or second-generation EGFR-TKIs [10]. How-
ever, approximately 40%-60% of patients who develop resist-
ance to EGFR-TKIs still need chemotherapy. Although pla-
tinum doublet chemotherapy is recommended as the treat-
ment of choice in those patients, few data exist regarding the
use of conventional chemotherapy for second-line treatment
after failure of first-line EGFR-TKIs. D'Addario et al. [11] 
reported a 34.1% response rate and PFS of 6.8 months for a
gemcitabine plus cisplatin regimen in NSCLC patients after
failure of gefitinib. Wu et al. [12] performed retrospective
analysis of second-line treatments after first-line gefitinib
therapy and showed that platinum-based combination
chemotherapy was associated with better PFS and overall
survival (OS) than non-platinum regimens containing taxane
or erlotinib. 
Pemetrexed, a multi-target anti-folate agent, has been 
approved as second-line therapy regardless of first-line ther-
apy (chemotherapy or targeted agents) in Korea, and only
single-agent pemetrexed is available for patients who fail
EGFR-TKIs. Our recent retrospective analysis showed that a
combination of pemetrexed plus platinum had a better dis-
ease control rate than pemetrexed alone, suggesting the ben-
efit of platinum doublets after failure of first-line EGFR-TKIs
[13]. Moreover, the role of single-agent pemetrexed in this
patient population has not been fully evaluated.
Based on these data, we conducted a prospective random-
ized phase II trial to compare the clinical outcomes between
pemetrexed plus cisplatin combination therapy followed by
maintenance pemetrexed and pemetrexed monotherapy in
patients with EGFR-mutant NSCLC that progressed after
first-line treatment with EGFR-TKIs.
Materials and Methods
1. Patient eligibility
We recruited patients who were at least 20 years old and
had Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0 or 1, histologically confirmed non-squamous
NSCLC harboring activating EGFR mutation (exon 19 dele-
tion or L858R mutation on exon 21), and stage IIIb, IV, or 
recurrent disease that progressed after first-line treatment
with EGFR-TKIs. Other detailed inclusion criteria were as
follows: at least one measurable lesion by Response Evalua-
tion Criteria in Solid Tumors (RECIST) 1.1; asymptomatic
brain metastasis or symptomatic brain metastasis treated
with local treatment such as operation, whole brain radio-
therapy (WBRT), or stereotactic radiosurgery (SRS); at least
2 weeks after WBRT or palliative radiotherapy (in the case
of SRS, treatment delay was not required); adequate organ
function; no other previous systemic cytotoxic chemotherapy
(adjuvant or neoadjuvant chemotherapy was allowed); and
provision of written informed consent. Exclusion criteria 
included uncontrolled systemic illness such as diabetes, heart
failure, unstable angina, hypertension, or arrhythmia; post-
obstructive pneumonia or uncontrolled serious infection;
pregnant or nursing women (women of reproductive poten-
tial had to agree to use an effective contraceptive method);
uncontrolled symptomatic brain metastasis or presence of a
third space that could not be controlled by drainage; prior
history of malignancy within 5 years from study entry except
for adequately treated basal cell or squamous cell skin can-
cer, in situ cervical cancer, or well-treated thyroid cancer.
2. Study design, endpoints, and treatments
In this multicenter, randomized, open-label, phase II trial,
the primary endpoint was to compare PFS of pemetrexed
plus cisplatin combination chemotherapy and pemetrexed
as a single agent. Secondary endpoints included overall 
response rate (ORR), OS, safety and toxicity profiles, and
health-related quality of life (HRQOL).
Eligible patients were randomly assigned in a 1:1 ratio to
a pemetrexed plus cisplatin combination followed by main-
tenance pemetrexed (PC) arm and a pemetrexed only (P)
arm. Block randomization and a non-stratified method were
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used. Patients in the PC arm were treated with four cycles of
pemetrexed 500 mg/m2 and cisplatin 70 mg/m2 intrave-
nously, followed by maintenance pemetrexed as a single
agent for every 3 weeks until progression of disease (PD). 
Patients in the P arm were treated with pemetrexed 500
mg/m2 monotherapy every 3 weeks until PD. Patients 
received vitamin B12, folate, and dexamethasone treatment
as premedications for pemetrexed. Dose reductions, delays,
and discontinuations due to toxicity were specified by the
protocol. 
3. Response and toxicity assessments
RECIST 1.1 criteria were used to assess the response to
treatment by determining PFS and ORR. Tumor assessment
by computed tomography was performed at baseline and 
repeated every other cycle until progression. Other follow-
up assessments including laboratory tests and chest X-ray
were repeated every cycle. After progression, patients con-
tinued to be followed up for survival every 8-12 weeks until
death. Analyses for efficacy and safety were performed with
patients receiving at least one dose of any study drug. Toxi-
city was assessed in accordance with the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events
ver. 4.0. The HRQOL was assessed every two cycles using a
validated Korean version of EORTC QLQ-C30 ver. 3.0 and
EORTC QLQ-LC13. The QLQ-C30 is composed of five func-
tional scales, three symptom scales, and global health status,
and analyses were performed separately according to these
domains.
4. Statistical analysis
This study was designed as a phase 2 trial, and we calcu-
lated the sample size based on the results of previous phase
3 trials [14,15]. We assumed that the control arm (P arm)
would have a median PFS of 3 months, and we were inter-
ested in the experimental arm (PC arm) for further investi-
gation if its median PFS is 6 months or longer. To this end,
we needed 85 eligible patients for this study (42-43 patients
per arm). And assuming 10% dropout or ineligibility, appro-
ximately 96 randomly assigned patients (48 per arm) were
needed for PFS analysis based on (1) exponential PFS mod-
els, (2) one-sided alpha=5% and power=90%, (3) a monthly
accrual rate of 5-6 patients, and (4) an additional follow-up
period of 1 year. The final data analysis was conducted when
70 events of progression were observed. For each arm, PFS
and OS were summarized using the Kaplan-Meier method
and compared to those of the other arm using the log-rank
test. The response and toxicity were summarized using con-
tingency tables. The ORR and incidence rate of toxicity were
compared between the two arms using Pearson’s chi-square
From April 2013 to August 2015
Randomization 1:1 (n=96)
Analyzed for efficacy (n=46)
Analyzed for safety (n=46)
Analyzed for HRQOL (n=39)
Analyzed for efficacy (n=45)
Analyzed for safety (n=45)
Analyzed for HRQOL (n=32)
PC arm (n=48)
  Received chemotherapy (n=46)
  Treatment not started (n=2)
    Withdrawal of consent (n=2) 
Discontinued study treatment (n=46)
  Disease progression (n=37)
  Adverse events (n=2)
  Withdrawal of consent (n=4)
  Lost to follow-up (n=1)
  Violation of protocol (n=2)
Continuing study treatment (n=0)
Discontinued study treatment (n=40)
  Disease progression (n=33)
  Withdrawal of consent (n=5)
  Judgement by investigators (n=2)
Continuing study treatment (n=5)
P arm (n=48)
  Received chemotherapy (n=45)
  Treatment not started (n=3)
    Withdrawal of consent (n=2)
    Lost of follow-up (n=1) 
Fig. 1. Patient flow of this study. PC, pemetrexed plus cisplatin combination followed by maintenance pemetrexed; P, peme-
trexed only; HRQOL, health-related quality of life.
Cancer Res Treat. 2019;51(2):718-726
720 CANCER  RESEARCH  AND  TREATMENT
test or Fisher exact test. The HRQOL data were analyzed
using Student’s t test or Wilcoxon exact test individually or
by treatment arm. All tests of treatment effects were con-
ducted at a two-sided alpha level of 0.05, and all confidence
intervals (CIs) were given at a two-sided 95% level, unless
otherwise specified. Analyses were conducted using STATA
ver. 14.2 and R 3.2.2 (College Station, TX).
5. Ethical statement
All the patients provided written informed consent, and
the study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. And the
protocol was approved by each participating center’s insti-
tutional review board. 
Results
1. Patient characteristics
From April 2013 to August 2015, a total of 96 patients were
recruited from 14 centers in Korea and randomly allocated
to PC or P arms. Among 96 randomized patients, 46 in the
PC arm and 45 in the P arm were actually treated and formed
the target population of analyses for efficacy and safety. Five
patients who were not treated with investigational drugs due
to withdrawal of consent or loss to follow-up were excluded
from the analysis of efficacy and safety (Fig. 1). The clinical
data cutoff was October 13, 2016. Patients allocated to the
two arms were well balanced for baseline characteristics 
including age, sex, ECOG performance status, type of EGFR
mutation, and stage (Table 1). The median age of all patients
was 62 years, and 73% of patients were female. Patients in
the P arm showed a higher rate of smoking than those in the
PC arm, but without significance (p=0.104). Most of the 
patients were ECOG performance status 1 (85%). In both
arms, two-thirds of the patients had exon 19 deletions, and
one-third had L858R mutation. All patients were enrolled at
stage IV. Fifteen patients (16%) underwent curative surgery,
and 12 patients (13%) had received radiotherapy.
2. Treatment outcomes and survival
For the target population of efficacy analyses (n=91), the
median number of cycles administered for both PC and P
arms was 6 (range, 1 to 20 cycles for PC and 1 to 43 for P), 
although the mean number of cycles received was greater for
P than for PC (9.6 vs. 7.1, p=0.047). The ORR was 34.8%
(16/46) in the PC arm and 17.8% (8/45) in the P arm, without
statistical significance (p=0.066). The disease control rate was
78.3% (36/46) in the PC arm and 66.7% (30/45) in the P arm.
During chemotherapy, most patients maintained their initial
performance status, although 10 patients (11%) experienced
temporary worsening.
In a median follow-up of 23.4 months (range, 6.2 to 42.9
months), 70 patients showed disease progression, and 58
deaths occurred. The median PFS was 5.4 months (95% CI,
Table 1.  Patient characteristics
PC (n=48) P (n=48) Total (n=96) p-value
Age (yr) 60 (32-82) 64 (31-84) 62 (31-84) 0.133
Male sex 11 (23) 15 (31) 26 (27) 0.358
Smoking, yes 9 (19) 16 (33) 25 (26) 0.014
ECOG
0 9 (19) 5 (10) 14 (15) 0.247
1 39 (81) 43 (90) 82 (85)
EGFR mutation
Deletion exon 19 32 (67) 32 (67) 64 (67) > 0.999
L858R 16 (33) 16 (33) 32 (33)
Stage IV 48 (100) 48 (100) 96 (100) > 0.999
Recurrence 1 (2) 7 (15) 8 (8) 0.029
Metastatic 47 (98) 41 (85) 88 (92)
Surgery 6 (13) 9 (19) 15 (16) 0.399
Radiotherapy 4 (8) 8 (17) 12 (13) 0.178
Values are presented as median (range) or number (%). PC, pemetrexed plus cisplatin combination followed by maintenance
pemetrexed; P, pemetrexed only; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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4.5 to 6.3) in the PC arm and 6.4 months (95% CI, 3.3 to 5.5)
in the P arm, and there was no significant difference between
the two arms (p=0.114) (Fig. 2A). The median OS was 17.9
months (95% CI, 14.8 to 21.0) and 15.7 months (95% CI, 13.3
to 18.0) in the PC and P arms, respectively (p=0.787) (Fig. 2B).
3. Safety and toxicity profiles
For the target population of efficacy analyses (n=91), 75 
patients (82%) experienced one or more adverse events. The
most common adverse event was gastrointestinal toxicities
(n=44, 48.4%) including nausea, vomiting, diarrhea, and con-
stipation. Fatigue was the second most common adverse
event (n=25, 27.5%), followed by skin change and/or alope-
cia (n=13, 14.3%), neuropathy (n=10, 11.0%), and neutropenia
(n=6, 6.6%). Adverse events  grade 3 were observed in 12
patients (26.1%) in the PC arm and nine patients (20.0%) in
the P arm (p=0.491) (Table 2). Dose reduction (6 vs. 2 
patients) and treatment delay (10 vs. 4 patients) were requi-
red more often in the PC arm; however, the difference was
not significant (p=0.267 for dose reduction, p=0.145 for treat-
ment delay).
Fig. 2.  Kaplan-Meier survival curves of progression-free survival (PFS) (A) and overall survival (OS) (B). PC, pemetrexed
plus cisplatin combination followed by maintenance pemetrexed; P, pemetrexed only; CI, confidence interval.
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0.8
PC arm (n=46)
P arm (n=45)
p=0.114
5.4 mo (95% CI, 4.5-6.3) (PC) 
  vs. 6.4 mo (95% CI, 3.3-9.5) (P) O
S
1.0
0
0
Time (mo)
3525155 40302010 45
B
0.4
0.2
0.6
0.8
PC arm (n=46)
P arm (n=45)
p=0.787
17.9 mo (95% CI, 14.8-21.0) (PC) 
  vs.15.7 mo (95% CI, 13.3-18.0) (P)
PC (n=46) P (n=45) PC+P (n=91)                                               
Gr 1-2 Gr  3 Total Gr 1-2 Gr  3 Total Gr 1-2 Gr  3 Total
Fatigue 14 0 14 10 1 11 24 1 25
GI toxicity 22 4 26 18 0 18 40 4 44
Bleeding or thrombocytopenia 1 0 1 1 0 1 2 0 2
Neutropenia 1 2 3 0 3 3 1 5 6
Neurotoxicity 8 0 8 2 0 2 10 0 10
Skin and alopecia 5 0 5 8 0 8 13 0 13
Myalgia and arthralgia 2 0 2 4 0 4 6 0 6
Othersa) 25 8 33 27 5 32 52 13 65
Table 2. Safety and toxicity profiles
PC, pemetrexed plus cisplatin combination followed by maintenance pemetrexed; P, pemetrexed only; Gr, grade; GI, gas-
trointestinal. a)Others include headache, insomnia, dyspnea and pain on other sites than muscles and joints.
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4. HRQOL 
HRQOL data were obtained from 71 patients (39 in the PC
arm and 32 in the P arm) with 385 pairs of EORTC QLQ-C30
and QLO-LC13 questionnaires (185 pairs in the PC arm and
200 in the P arm). For functional scales, patients in the PC
arm showed a higher score than patients in the P arm at base-
line (p < 0.05); however, no significant differences were 
observed during follow-up. Likewise, patients in the P arm
recorded higher scores for symptom scales than patients in
the PC arm at baseline (p < 0.05), and there was no trend of
a difference in statistical significance during chemotherapy.
No significant difference was noted in global health status
between the two arms (Fig. 3). In assessment of lung cancer-
associated symptoms, treatment-related side effects, and
pain medication according to questions from the QLQ-LC13,
there were no trends of differences between the two arms
from baseline through the period of receiving chemotherapy.
Fig. 3.  Health-related quality of life (HRQOL) assessed by EORTC QLQ-C30. PC, pemetrexed plus cisplatin combination
followed by maintenance pemetrexed; P, pemetrexed only; CI, confidence interval.
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Discussion
This is the first prospective randomized study to compare
pemetrexed plus cisplatin combination therapy with single-
agent pemetrexed in patients who have failed first-line
EGFR-TKIs. We found that PFS as a primary endpoint was
not significantly different between the PC arm and the P arm
(5.4 months vs. 6.4 months, p=0.114). And ORR also did not
make statistically significant difference between two arms
(34.8 vs. 17.8%, p=0.066). Furthermore, the PC arm did not
show improved OS. Intriguingly, quality of life measured by
HRQ-OL was similar between the two arms. Our results sug-
gest that single-agent pemetrexed might be another treat-
ment option for patients with failure of first-line EGFR-TKI.
In general, platinum doublet chemotherapy, especially the
cisplatin/pemetrexed combination, has been considered
standard treatment in patients with failure of targeted agents
such as EGFR-TKIs or anaplastic lymphoma kinase inhibitors
as first-line therapy because these patients were not exposed
to cytotoxic chemotherapy. Single-agent pemetrexed is con-
sidered only for patients with poor performance or old age.
Accordingly, in the IMPRESS study, a randomized phase III
trial comparing gefitinib/chemotherapy and chemotherapy
in EGFR mutation-positive NSCLC resistant to first-line gefi-
tinib, the cisplatin plus pemetrexed combination was used
as the control arm [9]. A small-sized retrospective study 
reported prolonged PFS of pemetrexed singlet therapy com-
paring with nonpemetrexed-based platinum doublet after
failure of first-line EGFR-TKIs [16]. Most recently, however,
two studies published data indicating the efficacy of peme-
trexed-based combination chemotherapy as second-line
treatment after development of acquired resistance to first-
line EGFR-TKIs [17,18]. These studies mutually emphasized
the superiority of pemetrexed-containing regimens and com-
bination regimens with platinum in a retrospective analysis.
Our previous retrospective study also showed a trend favor-
ing platinum/pemetrexed compared with single-agent
pemetrexed in terms of ORR and PFS, which is inconsistent
with the results of the current study.
Pemetrexed is a multi-target anti-folate agent and exerts
its antitumoral effect mainly by inhibiting the thymidylate
synthase (TS) enzyme. Several retrospective and prospective
studies have reported an association between lower TS levels
and better clinical outcomes for pemetrexed-based chemo-
therapy [15,19,20]. We did not analyze TS level in this study;
however, considering that 5.4 months and 6.4 months of PFS
in the PC and P arms, respectively, the TS level might be dif-
ferent between two arms. Therefore, additional analysis for
the impact of TS expression on the efficacy of pemetrexed
after EGFR-TKIs should be performed. Actually, three pati-
ents in the P arm experienced long-term PFS around 30
months (from 28 to 35 months) and are still ongoing. Further
molecular analysis for these long-term responders to peme-
trexed monotherapy are warranted. Considering the results
of pemetrexed plus platinum therapy for NSCLC patients
with failure of EGFR-TKIs in both unselected and T790M-
positive populations [9,10], the PFS of 5.4 months and 6.4
months in the PC and P arms in this study would be quite
acceptable. Even though no significant differences were 
observed in PFS and OS between the two arms, PC combi-
nation therapy showed a relatively higher response rate and
might be a reasonable option for patients who require rapid
reduction of tumor burden.
Overall, the incidence of serious adverse events was simi-
lar between PC and P arms. Dose reduction and treatment
delay were required more often in the PC arm, although the
difference was not significant. Furthermore, quality of life 
assessed by EORTC QLQ-C30 and LC-13 did not show any
difference between the two arms. These results might imply
that both regimens are equally applicable and tolerable to 
patients whose disease progresses after EGFR-TKIs.
This study has several limitations. Repeat biopsy to evalu-
ate the resistance mechanism, including T790M, was not per-
formed. It has been reported that patients with the T790M
resistance mutation experience an indolent clinical course
[21-23]. Even though the two arms were well balanced in
terms of patient characteristics, genetic heterogeneity might
affect the clinical outcomes. Recently, a third-generation
EGFR-TKI, osimertinib, has been approved in patients with
T790M resistance mutation [24,25]. And another third-gen-
eration EGFR-TKI, olmutinib, received approval only in
South Korea for the treatment of patients with T790M muta-
tion-positive NSCLC [26]. Given that systemic chemotherapy
is considered standard treatment in T790M-negative pati-
ents, it remains undetermined whether the cisplatin plus
pemetrexed combination is better than single-agent peme-
trexed. Further studies are warranted for this subgroup of
the patient population.
In conclusion, pemetrexed plus cisplatin combination
treatment and pemetrexed monotherapy might be both 
effective and well tolerated in EGFR mutation–positive 
patients who show disease progression on first-line EGFR-
TKIs. These conventional regimens might be considered as
treatment options. 
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